Comorbidities in Patients with Psoriasis - 12/08/11
Reprint requests should be addressed to Alice B. Gottlieb, MD, PhD, Tufts Medical Center, 800 Washington St, Box 114, Boston, MA 02111-1533Abstract |
Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities. Patients with psoriasis have been shown to have an increased incidence of metabolic syndrome and cardiovascular disease compared with the general population. The chronic inflammatory nature of psoriasis has been suggested to be a contributing and potentially independent risk factor for the development of cardiovascular comorbidities. Understanding the interrelationship between these conditions is important for the management of psoriasis and the associated comorbidities. This review will focus on the range of comorbidities associated with psoriasis, with emphasis on cardiometabolic conditions and the aim of encouraging primary care physicians to screen psoriatic patients for cardiometabolic disorders and risk factors.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiovascular disease, Metabolic syndrome, Psoriasis, Psoriatic arthritis comorbidities
Plan
| Funding: Funding for writing assistance was provided by Amgen. |
|
| Conflict of Interest: Almost all of Dr Gottlieb's consulting and speaking fees are paid to Tufts Medical Center. Dr Gottlieb is a member of the speakers bureau of Amgen Inc, and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor, Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol-Myers Squibb Co, Beiersdorf, Inc, Abbott, Roche, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, Dermipsor Ltd., Incyte, Magen Biosciences, Stieffel, and Puretech; Tufts Medical Center has received research/educational grants from Centocor, Inc, Amgen Inc, Wyeth Pharmaceuticals, Immune Control, Celgene Corp, Pharmacare, Incyte, Novo Nordisk, Pfizer, and Abbott. Dr Dann is a former Amgen employee. He has participated on speakers bureaus for Amgen Inc and Wyeth Pharmaceuticals and has a consulting agreement with Amgen. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 122 - N° 12
P. 1150.e1-1150.e9 - décembre 2009 Retour au numéro
Article précédent
- Drug Burden Index Score and Functional Decline in Older People
- Sarah N. Hilmer, Donald E. Mager, Eleanor M. Simonsick, Shari M. Ling, B. Gwen Windham, Tamara B. Harris, Ronald I. Shorr, Douglas C. Bauer, Darrell R. Abernethy, Health ABC Study
- Effectiveness of Ribavirin and Corticosteroids for Severe Acute Respiratory Syndrome
- Eric H.Y. Lau, Benjamin J. Cowling, Matthew P. Muller, Lai-Ming Ho, Thomas Tsang, Su-Vui Lo, Marie Louie, Gabriel M. Leung
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?